Drug intelligence / Profile preview

ACT01 + Comp01

Development stage: Unknown
Lead developer: Promius Pharma, LLC
Modality: Small Molecules
Administration: Topical

Overview

Combination topical drug under investigation for the treatment of actinic keratosis; ACT01 and Comp01 are both applied as creams once daily for 29 days in clinical trials. The exact molecular identities, mechanisms, and components of ACT01 and Comp01 have not been fully disclosed in public clinical trial records. The combination’s safety and efficacy were investigated in a phase 2 clinical trial sponsored by Promius Pharma for the clearance of facial and/or scalp actinic keratosis lesions[1][3][4][5][7].

Other names: ACT01 + Comp01

Beyond the preview

Go deeper on ACT01 + Comp01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACT01 + Comp01.

Explore the full profile